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Abstract
AIM: �o assess the endoscopic activity �e�ore and a�ter        
a one-year period o� �iological therapy and to evalu-
ate the �requency o� relapses and need �or retreat�ent 
a�ter stopping the �iologicals in patients with Crohn’s 
disease �C��� and ulcerative colitis ��C���    
METHODS: �he data �ro� 41 patients with C� and 
22 patients with �C were assessed� �wenty-�our C� 
patients received in�lixi�a�, and 17 received adali�-
u�a�� �he endoscopic severity o� C� was quanti�ied 
with the si�plified endoscopic activity score �or Crohn’s 
disease in C� and with the Mayo endoscopic su�score 
in �C�
RESULTS: Mucosal healing was achieved in 23 C� and 
7 �C patients� Biological therapy had to �e restarted in 
78% o� patients achieving co�plete �ucosal healing 
with C� and in 100% o� patients with �C� Neither clini-
cal re�ission nor �ucosal healing was associated with 
the ti�e to restarting the �iological therapy in either 
C� or �C�
CONCLUSION: Mucosal healing did not predict sus-
tained clinical re�ission in patients in who� the �io-
logical therapies had �een stopped�
© 2014 Baishideng Pu�lishing Group Co�, Li�ited� All rights 
reserved�
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Core tip: Mucosal healing has �eco�e a su��ect o� 
renewed interest, as tu�or necrosis �actor-  α �lockers 
have proven their e�ficacy in inducing and �aintaining 
clinical and endoscopic re�ission� In this study, �uco-
sal healing was o�served in 56% and 32% o� Crohn’
s disease �C��� and ulcerative colitis ��C�� patients�      
Retreat�ent with �iological therapies was required 
in 78% o� C� patients and in 100% o� �C patients, 
despite achieving �ucosal healing within 12 �o� Our 
results showed that �ucosal healing a�ter 12 �o o� 
treat�ent was not associated with sustained clinical 
re�ission�
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Colonoscopies still play an important role in the diagno-
sis, management and monitoring of  inflammatory bowel 
disease (IBD) - a chronic, relapsing inflammatory condi-
tion of  the gut. IBD comprises Crohn’s disease (CD) and 
ulcerative colitis (UC). Mucosal healing is now regarded 
as one of  the most important goals in the treatment 
of  IBD, considering that mucosal healing can alter the 
course of  the disease due to its association with sustained 
clinical remission and reduced rates of  hospitalization 
and surgery[1]. Although endoscopy provides a direct 
evaluation of  the mucosal lesions in IBD and intestinal 
activity may be quantified by indices of  endoscopic activ-
ity, a clear definition of  mucosal healing is still lacking. 
Most of  the clinical trials on CD define mucosal healing 
as the total disappearance of  mucosal ulcerations[2]. The 
simplified endoscopic activity score for Crohn’s disease 
(SES-CD), developed by Daperno et al[3] has become a 
relatively easy tool for the assessment of  mucosal lesions 
in CD, although it is not widely used in practice. In UC, 
several endoscopic indices have been used in clinical trials 
to evaluate the endoscopic activity[4]; however, the Mayo 
endoscopic score remains the most commonly used, not 
only in trials but also in clinical practice[5]. The weak-
nesses of  these endoscopic activity indices include the 
absence of  a clear definition and the lack of  validation of  
mucosal healing[6].
Mucosal healing has become a subject of  renewed 
interest, as TNF-α blockers have proven their efficacy in 
inducing and maintaining clinical and endoscopic remis-
sion in both CD and UC. In CD, the effect of  infliximab 
on mucosal healing has been examined in substudies of  
larger clinical trials. In the substudy of  the ACCENT I 
trial[7], 50% of  patients receiving scheduled infliximab 
achieved mucosal healing at week 54.
Routine endoscopic follow-up is recommended for 
all CD patients who have achieved clinical remission with 
medical therapy; for those with persistent complaints, in 
order to rule out post-inflammatory irritable bowel syn-
drome; for those still within their first year after surgery; 
and for those who are stopping biological therapies but 
continuing immunosuppressants[8,9]. Combined immuno-
suppression is seems to be associated with higher rates 
of  mucosal healing therefore treatment intensification is 
not recommended. However, mucosal healing at the time 
of  treatment withdrawal may predict better outcomes in 
CD[2]. 
According to the Hungarian reimbursement regula-
tions (National Health Insurance Fund Administration), 
biological therapies (infliximab approved for the treat-
ment of  CD and UC and adalimumab approved for the 
treatment of  CD) have to be discontinued after a one-
year treatment period. The endoscopic healing of  the 
mucosa is commonly evaluated at the end of  the one-year 
treatment period with anti-TNF blockers in the Hungar-
ian biological centers. In the present study, our aim was 
to assess the endoscopic activity and the rate of  mucosal 
healing after a one-year period of  biological therapy and 
to evaluate how the endoscopic findings of  the mucosa 
predict the frequency of  relapses and the need for re-
starting biological therapy after stopping in patients with 
CD and UC.
MATERIALS AND METHODS
Study design and patients
This was a prospective observational study conducted at 
2 Hungarian tertiary referral biological centers in the First 
Department of  Medicine, University of  Szeged and First 
Department of  Medicine, Semmelweis University between 
January 2010 and December 2011. The study was ap-
proved by the Semmelweis University Regional and Insti-
tutional Committee of  Science and Research Ethics and by 
the Regional and Institutional Human Medical Biological 
Research Ethics Committee of  the University of  Szeged. 
The analysis focused on patients who underwent an ileoco-
lonoscopy before and after the one-year biological therapy 
and in whom anti-TNFs were discontinued at the end of  
the year. Endoscopies were performed by four experienced 
gastroenterologists (Molnár T, Lakatos PL, Nagy F, and 
Szepes Z) after stopping the one-year biological therapy.
Forty-one consecutive CD patients (25 females, 16 
males, mean disease duration at the beginning of  biologi-
cal therapy: 5 years) and 22 UC patients (14 females, 8 
males, mean disease duration at the beginning of  biologi-
cal therapy: 9.1 years) were prospectively followed up in 
this study. All patients received maintenance infliximab 
or adalimumab therapy for one year in accordance with 
Hungarian regulations. Diagnosis was based on the 
Lennard-Jones Criteria[10]. CD disease phenotypes were 
determined according to the Montreal Classification[11]. 
Twenty-four CD patients received infliximab, and 17 
received adalimumab. All of  the UC patients received 
infliximab. These patients received the last dose of  bio-
logical therapy at least 3 mo before the repeated one-year 
therapy. Twenty-eight patients were naive to biologi-
cal therapy (did not receive biological therapy before 
the one-year treatment period analyzed in the study) in 
the CD group, and 21 patients, in the UC group. The 
concomitant immunosuppression during the induction 
therapy was steroids in 42 and azathioprine in 51 patients. 
The clinical characteristics of  the patients are presented 
in Table 1. Patient data regarding smoking status, previ-
ous appendectomy, perianal involvement, presence of  ex-
traintestinal manifestation, concomitant immunosuppres-
sive medications, outcome of  induction therapy, previous 
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surgical procedures, and previous biological therapy were 
collected. Biopsy samples were not taken routinely.
Assessment of clinical and endoscopic remission based 
on biological therapy
Clinical activities, as determined by the Crohn’s Disease 
Activity Index (CDAI - with hematocrit value)[12] in CD 
and by the Mayo score[4] in UC, were calculated at the 
end of  the biological therapy when the endoscopic as-
sessment was performed, while partial Mayo scores were 
calculated when biological therapy needed to be restarted. 
Clinical remission was defined as a CDAI of  <� 150  
points and a Mayo score of  <� 2 points. Sustained clini-
cal remission was defined as a stable, steroid-free clinical 
remission during the 1-year follow-up period. The defini-
tion of  relapse and indication for restarting biologicals 
were an increase of  >� 100 points in CDAI and a CDAI        
of  >� 150 points and a partial Mayo score of  >� 3 points.  
The endoscopic severity of  CD was quantified with 
SES-CD in CD[2] and with Mayo endoscopic subscore in 
UC[4]. The endoscopic scores were prospectively assessed 
by two investigators (Molnár T, Lakatos PL). Mucosal 
healing was defined using the endoscopic indices as SES-
CD between 0 and 3 and Mayo endoscopic subscore as 0.
Endpoints
Data collection and analysis were performed at the 1st 
Department of  Medicine at the University of  Szeged. The 
primary endpoint of  the study was the proportion of  mu-
cosal healing in IBD after the one-year period of  biologi-
cal therapy. The secondary endpoint was the frequency of  
relapses in the next year after achieving mucosal healing.
Statistical analysis
Variables were tested for normality using Shapiro-Wilk’s 
W test. The χ 2-test and χ 2-test with Yates correction and 
logistic regression analysis were used to assess the as-
sociation between categorical clinical variables and clini-
cal/endoscopic outcomes. The variables analyzed were 
gender, disease duration, active smoking, appendectomy, 
location/extent, behavior, associated perineal disease, 
type of  anti-TNF agent, extraintestinal manifestations, 
steroid and azathioprine therapy during the induction pe-
riod, previous surgery, previous biological therapy, clinical 
activities, CRP levels (mg/L), and outcomes of  induction 
therapy. The difference between patients with mucosal 
healing and those who failed to achieve endoscopic re-
mission was assessed by chi-square or Fisher’s exact tests. 
Kaplan-Meier survival curves were plotted for analysis 
with the Log-Rank and Breslow tests. A P value <� 0.05 
was considered significant. For the statistical analysis, 
SPSS15.0 (SPSS Inc., Chicago, IL) was used.
RESULTS
Clinical activity of CD and UC after the one-year period 
of biological therapy
The median CDAI was 60 (interquartile range: 39.3-96) (P 
< 0.001) and the partial Mayo score was 0 (interquartile 
range: 0-4) (P < 0.001) at the end of  the treatment pe-
riod. A total of  35/41 patients with CD (85%) and 12/22 
with UC (55%) achieved clinical remission at the end of  
the year of  biological therapy. 
Endoscopic activity of CD and UC before and after the 
one year period of biological therapy
Colonoscopies reached the terminal ileum in every case. 
The median values of  the SES-CD and the Mayo endo-
scopic subscores significantly improved after the anti-TNF 
therapy �16 (interquartile range: 12-23)    vs 5 (interquartile  
range: 3-9), P < 0.001, and 3 (interquartile range: 2-3)    vs 1 
(interquartile range: 0-2),   P < 0.001�. Mucosal healing was    
achieved in 23 CD (56%) and 7 UC (32%) patients. At 
the end of  one year of  treatment, clinical remission was 
achieved in 96% of  CD patients with mucosal healing and 
in 71% of  UC patients with mucosal healing. Deep remis-
sion - both mucosal healing and clinical remission - was 
achieved in 22 CD and 5 UC patients.
Table 1  Demographic and clinical characteristics of patients 
enrolled in the study
CD patients 
(n  = 41)
UC patients 
(n  = 22)
Female/male 25/16 14/8
Mean age at diagnosis (yr) 28 (15-59) 33 (14-53)
Mean age at the beginning of 
biological therapy (yr)
32 (20-62) 43 (17-66)
Age at diagnosis
   < 16 yr (A1)     4   2
   17-40 yr (A2)   31 14
   > 40 yr (A3)     6   6
Location 
   Ileal (L1)     6 -
   Colonic (L2)     7 -
   Ileocolonic (L3)   28 -
   Upper GI (L4)     0 -
   Proctitis -   0
   Left-sided colitis - 14
   Extensive colitis -   8
Behaviour 
   Inflammatory (B1)   12 -
   Stricturing (B2)     8 -
   Penetrating (B3)   21 -
   Perianal manifestation   23 -
Extraintestinal manifestation   26   9
Concomitant medications
   Corticosteroids   32 10
   Azathioprine   35 16
Surgery before the biological 
therapy
  19   3
Previous biological therapy   13   1
Median CDAI/pMayo at the 
start of biological therapy
340   8
Median CRP level at the start 
of biological therapy (mg/L)
  10    9.5
Current smokers   18 0
Appendectomy     7 0
CD: Crohn’s disease; UC: Ulcerative colitis; GI: Gastrointestinal; CRP:   
C-reactive protein; CDAI: Crohns disease activity index.
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DISCUSSION
In this prospective observational study conducted in pa-
tients with CD and UC receiving biological therapy for 
one year, mucosal healing was observed in 56% and 32% 
of  the patients, respectively. Deep remission, including 
both clinical and endoscopic remission, was detected in 
54% and 23% of  patients with CD and UC. Retreatment 
with biological therapy was necessary in 78% of  CD pa-
tients and in 100% of  UC patients, despite their achiev-
ing mucosal healing within 12 mo. Our results showed 
that mucosal healing after 12 mo of  treatment was not 
associated with sustained clinical remission.
Mucosal healing seems to be associated with better 
outcomes (reduced rate of  hospitalization, complica-
tions, surgery) in CD[13,14]. The study of  Ananthakrishnan 
demonstrated that mucosal healing as an endpoint is cost 
effective in CD patients initiating infliximab therapy[15]. In 
a Norwegian study, mucosal healing was associated with 
lower colectomy rate in UC and decreased need for ste-
roid treatment in CD[16]. The STORI trial suggested that 
one of  the predictors of  relapse after discontinuation of  
biological therapy was the absence of  mucosal healing at 
the time of  drug withdrawal[9]. The study of  Baert et al[17] 
confirmed that complete mucosal healing after 2 years 
of  therapy in patients with early stage CD predicted sus-
tained steroid-free remission 3 and 4 years after therapy 
was initiated.
Regarding the therapeutic repertoire of  IBD, biologi-
cal agents proved to be the most effective in inducing 
mucosal healing. The ACCENT Ⅰ study confirmed that 
scheduled infliximab therapy is more effective in achiev-
ing mucosal healing than episodic treatment[14] for CD. 
The beneficial effect of  the combined use of  infliximab 
and azathioprine on mucosal healing was proven by the 
SONIC trial, in which the achievement of  mucosal heal-
ing occurred in 44% of  patients receiving both thera-
pies[18]. In the EXTEND trial, 24% of  adalimumab-treat-
ed patients reached complete mucosal healing at week 
Need for restarting biological therapy and association 
between mucosal healing and restarting biological 
therapy
During the one-year follow up period, 11 patients in the 
clinical remission group and 18 patients in the deep remis-
sion group had to be retreated. In CD, biological therapy 
was restarted due to clinical relapse in 32 (78%) patients 
after a median 5 mo (interquartile range: 3.5-6 mo). The 
median CDAI was 332 (interquartile range: 121-371) at 
the time of  relapse. In UC, biological therapy needed to 
be restarted in 13 patients (59%) after a median 7.5 mo 
(interquartile range: 4-11 mo). The median partial Mayo 
score was 6.5 (interquartile range: 5.3-7) at the time of  
retreatment. Of  note, therapy was restarted in the two 
patients who achieved mucosal healing, and 5 of  the 7 
patients who achieved clinical remission and all 5 patients 
who achieved deep remission had to be retreated within 
one year. Endoscopic activity was not assessed in every 
patient when the biological therapy was restarted. The re-
sponse rates for retreatment were 81% in CD and 54% in 
UC within an average of  8 wk after the reintroduction of  
the therapy.
In a univariate or Kaplan-Meier analysis using the 
Log-Rank and Breslow tests, neither clinical remission 
nor mucosal healing was associated with the time to re-
starting biological therapy in either CD (Figure 1) or UC. 
In univariate analysis, none of  the investigated parame-
ters (e.g., gender, disease duration, smoking status, history 
of  appendectomy, location/extent, behavior, the type 
of  anti TNF-α therapy, extraintestinal manifestations, 
steroid therapy at inclusion, previous surgery, previous 
biological therapy, CRP level, or the effect of  induction 
therapy) was associated with the need to restart biological 
therapy in either CD or UC (Table 2). No association was 
found between combined immunomodulator therapy and 
mucosal healing (Table 2).
Figure 1  ��������eier ������i� u�i�g ��g������ ���� �re����� �e����� ��i�i�       
��� remi��i�� �r mu����� he��i�g ���� ��� �����i��e�� ��i�h �he �ime �� 
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Table 2  Univariate regression analysis of need for retreatment 
with biologicals
Factor CD-P  value UC-P  value
Gender 0.98 0.57
Disease duration 0.09 0.12




Type of anti TNF-α therapy 0.73 -
Extraintestinal manifestations 0.35 -
Steroid therapy at inclusion 0.15 0.09
Previous surgery 0.99 -
Previous biological therapy 0.38 -
Elevated CRP level 0.47 0.97
Combined immunomodulator use 0.22 0.59
Outcome of induction therapy 0.30 0.29
TNF-α: Tumor necrosis factor-α; CD: Crohn’s disease; UC: Ulcerative      
colitis; CRP: C-reactive protein.
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52[19]. The ACT trials confirmed the efficacy of  infliximab 
in inducing and maintaining mucosal healing in active 
UC[7]. The combined use of  infliximab and azathioprine 
resulted in 63% mucosal healing in the SUCCESS trial[20]. 
In our study, anti TNF-α therapy proved to be more ef-
fective in achieving mucosal healing in CD than in UC 
(almost twice as many CD patients achieved endoscopic 
remission as UC patients). This result may be due to the 
difference in the sizes of  the inflamed area, the enrolled 
patient number and the proportion of  patients with pre-
vious biological therapy in the CD and UC groups. No 
differences were detected in the efficacy between inflix-
imab and adalimumab; however, it should be noted that 
adalimumab was used in a lower number of  patients.
In the future, an important question for discussion 
is exactly when mucosal healing should be established. 
International guidelines recommend assessing endo-
scopic healing after stopping the therapy with anti-TNF 
agents. Our results do not support this recommendation 
after one-year therapy because more than 80% of  the 
patients with mucosal healing relapsed and needed re-
treatment. From another point of  view, to date, there is 
no established guideline on when biological therapy can 
be discontinued. According to the recent London Posi-
tion Statement of  the World Congress of  Gastroenterol-
ogy on Biological Therapy for IBD, the withdrawal of  
biological therapy is suggested in CD patients who have 
both complete mucosal healing and no biological evi-
dence of  inflammation[21]. In our study, 85% of  patients 
with deep remission relapsed within a year. The response 
rates for retreatment were 81% in CD and 54% in UC. 
In the STORI study, infliximab therapy was terminated 
in 115 CD patients in clinical remission after treatment 
with a combination of  scheduled infliximab and a stable 
dose of  immunosuppressant for at least one year[9]. For-
ty-five percent of  patients relapsed following withdrawal 
from infliximab. Re-treatment with infliximab was ef-
fective and well tolerated in 88% of  patients who expe-
rienced a relapse. In a Danish single-center study, 24% 
of  CD patients and 30% of  UC patients discontinued 
infliximab while in clinical steroid-free remission[22]. The 
proportion of  patients in remission declined steadily, 
with 61% of  CD patients and 75% of  UC patients re-
maining in remission after 1 year. Half  of  these patients 
maintained their remission after a median of  2 years. 
In total, 96% of  CD patients and 71% of  UC patients 
experienced complete clinical remission when retreated 
with infliximab after their relapses. In the longitudinal 
cohort study by Waugh et al[23] 50% of  patients relapsed 
within 477 d, while 35% remained in sustained clinical 
remission for nearly 7 years.
There are some limitations of  this study that should 
be mentioned. First, biopsy samples were not taken rou-
tinely to assess microscopic activity of  IBD. Theoretically, 
the microscopic evaluation of  the mucosa reflects the 
therapeutic response more accurately than an endoscopy, 
but it should be noted that the histological assessment of  
biopsy samples demonstrates only mucosal abnormalities. 
In CD, the transmural pattern is difficult to evaluate[24] in 
this way. The recently published paper by Bessissow et al[25] 
demonstrated that the presence of  basal plasmacytosis 
predicts UC clinical relapse in patients with complete mu-
cosal healing (OR = 5.13, 95%CI: 1.32-19.99).
Moreover, the study of  Laharie et al[26] did not find any 
correlation between histologically confirmed microscopic 
inflammation and endoscopic activity indices. Therefore, 
the need for microscopic evaluation in the assessment of  
mucosal healing may be worth reassessing. Second, the 
sample size is a bit small to draw significant conclusions, 
although we think that the tendency of  these results is 
interesting and worth considering. Third, there is no uni-
versal agreement regarding an acceptable definition of  
mucosal healing. In this study, mucosal healing was evalu-
ated on the basis of  validated endoscopic activity indices; 
however, in clinical practice, the disappearance of  muco-
sal ulcers and erosions may be used more frequently.
Currently, the primary goals of  treatment in IBD are 
not only the induction and maintenance of  clinical re-
mission but also the induction of  mucosal healing in an 
attempt to alter the course of  the disease. Endoscopy is 
still the gold standard method of  assessing changes of  the 
mucosa. Considering that the macroscopic findings of  the 
mucosa represent its real alterations after the initiation of  
a new therapy, mucosal healing represents a more reliable 
and objective marker in the assessment of  therapeutic 
response than clinical activity indices. However, none of  
the studies mentioned above support that mucosal healing 
correlates with clinical activity. Our results also revealed a 
high proportion of  patients who relapsed after mucosal 
healing. The higher relapse rates in patients who achieved 
mucosal healing may be explained by the shorter duration 
of  their biological therapy and less frequent use of  com-
bined immunosuppressive therapy than in previous similar 
studies. In this respect, our results call into question the 
routine endoscopic examinations at the end of  the one-
year period of  biological therapy. Stopping or continuing 
the biological therapy may be determined by assessing the 
patient’s general condition and the clinical activity. Cer-
tainly, large controlled clinical trials are required to con-
firm these results. However, based on our observations, 
we conclude that the long-term advantages of  mucosal 
healing can be achieved only if  we continue previous ef-
fective therapies, even after the endoscopic examination.
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tions performed at the end of the one�year period of biological therapy.
Peer review
�his is an interesting study with the important message that mucosal healing 
does not predict “sustained” clinical remission if the biologicals are stopped 
after one year of treatment.
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